Brenda Finucane is associate director of the Autism and Developmental Medicine Institute at Geisinger in Lewisburg, Pennsylvania.
Brenda Finucane
Associate director
Autism and Developmental Medicine Institute at Geisinger
From this contributor
Q&A with Brenda Finucane: Building pipelines for genetic tests for autism
Most autistic people do not receive the medically recommended genetic tests for autism. Brenda Finucane and her colleagues want to change that.
Q&A with Brenda Finucane: Building pipelines for genetic tests for autism
By
Angie Voyles Askham
17 August 2021 | 6 min read
Explore more from The Transmitter
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
By
Magdalena Paluchowska
13 July 2026 | 8 min read
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
By
Natalia Mesa
9 July 2026 | 5 min read
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
By
Kenneth Harris
9 July 2026 | 9 min read